GEHC 850 Technology Image 1 v1
technology

Engineered to inform

All our new 800 Series SPECT/CT systems build on the success of the 600 Series with a collection of SPECT technology enhancements that add to the value of nuclear medicine. In addition to the all-new SmartConsole, these enhancements include a new LEHRS (Low Energy High Resolution and Sensitivity) collimator, which can be combined with either SPECT Step & Shoot Continuous scanning mode or our Planar Clarity 2D processing to increase sensitivity and enable a reduction of scan times or injected dose1. It’s called SwiftScan Planar and SwiftScan SPECT. NM/CT 850 also includes the Elite NXT detectors, designed to address some of nuclear medicine’s biggest challenges.

With the range of CT technology available today, you don’t necessarily need a high-powered, diagnostic CT to get the benefits of anatomical information for your SPECT images. NM/CT 850 includes our Revolution™ ACTs CT system, which has been adapted to provide the low-dose scanning specifically needed for localization and attenuation correction in nuclear medicine hybrid imaging. It’s an eight-slice CT system with many of the image-quality-enhancing technologies that were previously limited to high-end, diagnostic CT systems. It’s a much more compact system with the essential CT technologies you need to provide advanced SPECT/CT exams without the extra cost and siting requirements of a 16-row detector CT.
  • Modular system design allows for a simple, on-site upgrade without having to do a complete system swap
  • Utilize the proven platform of NM/CT 850 and upgrade to NM/CT 860 when you are ready to add standalone diagnostic CT capabilities
  • Reduce cost and save space by sharing collimators with existing 600 Series and 800 Series systems
  • Cost-effective access to future innovation
  • Access future image quality enhancements and Cloud Analytics with the future-ready SmartConsole
  • Modular system design allows for a simple, on-site upgrade without having to do a complete system swap
  • Utilize the proven platform of NM/CT 850 and upgrade to NM/CT 860 when you are ready to add standalone diagnostic CT capabilities
  • Reduce cost and save space by sharing collimators with existing 600 Series and 800 Series systems
  • Cost-effective access to future innovation
  • Access future image quality enhancements and Cloud Analytics with the future-ready SmartConsole
GEHC 850 Capability Image 1 v1
capability

One diagnostic insight on top of another

NM/CT 850 combines the 800 Series SPECT enhancements with the thin-slice performance of Revolution ACTs to deliver one diagnostic insight on top of another. You can increase confidence in your images with the improved specificity and sensitivity of SPECT/CT over SPECT-only images. In addition, SmartConsole and Xeleris™ make more advanced hybrid and quantitative protocols available in routine settings by reducing the resources needed to perform them. It’s all the clinical value of SPECT/CT, in a smaller package. The perfect amount of capability to start detecting disease earlier with the potential to add standalone diagnostic CT capabilities in the future.

A simpler way to bring everything together




Q.Volumetrix MI is an Xeleris 4 DR application that integrates SUV measurements directly into the volume viewer. It allows you to see both the image and the SUV simultaneously instead of having to switch back and forth between two separate applications. Then, with SmartConsole, your quantitative SPECT/CT studies are automatically transferred directly to the PACS or other pre-defined DICOM destination. These resource-saving improvements allow you to expand your services to offer these advanced protocols without breaking your schedule.

Stay on top of the latest trends in imaging




NM/CT 850 allows you to provide referring physicians with a wide range of valuable services, including emerging trends in surgical and therapy planning. Services like the ability to calculate a lung cancer patient’s current lung capacity and accurately estimate what their post-operative lung capacity will be. And the ability to provide surgeons with a roadmap to find and remove affected nodes during sentinel node dissections. In addition, Revolution ACTs has the dose reduction technology referring physicians expect with every SPECT/CT exam.
GEHC 850 Future-Ready Image 1 v1
future-ready

A system that’s ready for the future when you are

NM/CT 850 shares the same modular design as the rest of the 800 Series family of nuclear medicine systems. They all share a common user interface and collimators, which makes it easier both operationally and financially to upgrade to another 800 Series system or to add another system to your overall asset mix.

Its modular design also means you have the option to purchase SPECT advancements like SwiftScan Planar and SwiftScan SPECT now, or in the future. In addition, NM/CT 850 has a small footprint that is easy to site in smaller rooms. And it has an easy upgrade path to the standalone diagnostic CT capability of NM/CT 860 should your organization require it in the future.
GEHC 850 Quantitative Applications Image 1 v1
quantitative applications

Inform your decisions with measurable results

The Xeleris workstation is our Nuclear Medicine, PET, NM/CT and PET/CT processing, analysis and review system. It’s designed to leverage the latest in SPECT quantitative applications for routine clinical use, accelerate workflow and improve diagnostic confidence. It also opens the door to the new era of digital healthcare delivery through its potential to access the GE Health Cloud and with advanced applications to help solve some of the most complex clinical presentations.

  • Q. Volumetrix MI

    Q.Volumetrix MI enables routine quantitative SPECT results in the form of MBq/ml and SPECT SUV without workflow impediments for both base line and longitudinal studies.

  • Q. Volumetrix MI

    Q.Volumetrix MI integrates SUV measurements directly into the volume viewer, so you can see both results in the same application.

  • Q. Brain

    Accurately diagnose neurodegenerative diseases with Q.Brain.

  • DaTQUANT™

    Improve neurologic SPECT workflow with fast, reproducible and accurate quantitation of 123I Ioflupane with DaTQUANT.

  • Q. Lung

    Diagnose pulmonary embolism by identifying V/Q mismatch with Q.Lung.

  • Q. Lung

    Confidently classify patients eligible for lung resection surgeries with Q.Lung.

  • Dosimetry Toolkit

    Plan radioisotope therapy by measuring changes in tracer absorption over time with Dosimetry Toolkit.
GEHC 850 Summary Image 1 v1
summary

A SPECT/CT system for true discovery

Molecular imaging is unlike any other imaging technology because it enables the search for true discovery. It’s the type of discovery that reveals a new way to understand something hidden deep within us. It’s what inspires confidence in the accuracy of what you see and in your ability to find disease sooner. It’s this diagnostic confidence that strengthens the value of nuclear medicine throughout the healthcare community.

Continuing to grow the clinical value of SPECT/CT technology takes as much of a commitment from the people who use it as it does from the people who make it. You, like us, are committed to making true discovery even more accessible to the patients you serve. It’s why we partnered with you to better understand what your financial and operational challenges might be. It’s also why we created NM/CT 850 to help you overcome those challenges, so you can continue to pursue true discovery.

Related Products

  • 1 Compared to LEHR collimator, with Step & Shoot scan mode (for SPECT) / without Clarity 2D (for Planar). As demonstrated in phantom testing using a bone scan protocol, Evolution processing (for SPECT), and a model observer. Because model observer results may not always match those from a human reader, the actual time/dose reduction depends on the clinical task, patient size, anatomical location and clinical practice. A radiologist should determine the appropriate scan time/dose for the particular clinical task.
  • 2 In clinical practice, Evolution options2a (Evolution for Bone, Evolution for Cardiac, Evolution for Bone Planar) and Evolution Toolkit2b are recommended for use following consultation of a Nuclear Medicine physician, physicist and/or application specialist to determine the appropriate dose or scan time reduction to obtain diagnostic image quality for a particular clinical task, depending on the protocol adopted by the clinical site.
  • 2a Evolution Options - Evolution claims are supported by simulation of count statistics using default factory protocols and imaging of 99mTc based radiotracers with LEHR collimator on anthropomorphic phantom or realistic NCAT – SIMSET phantom followed by quantitative and qualitative images comparison.
  • 2b Evolution Toolkit - Evolution Toolkit claims are supported by simulation of full count statistics using lesion simulation phantom images based on various radiotracers and collimators and by   showing that SPECT image quality reconstructed with Evolution Toolkit provide equivalent clinical information but have better signal-to-noise, contrast, and lesion resolution compared to the   images reconstructed with FBP / OSEM.
  • 3 As demonstrated in phantom testing using a model observer. For SPECT, compared to using the LEHR Collimator and a SPECT Step & Shoot acquisition. For Planar, compared to using LEHR without Clarity 2D.
  • 4 Compared to Optima™ NM/CT 640, as demonstrated in phantom testing.

JB01497IN

WIPRO GE HEALTHCARE PVT LTD
No. 4, Kadugodi Industrial Area,
Bangalore 560067,
Karnataka, India
CIN: U33111KA1990PTC01606
1800-102-2977 / +91 80 4180 1290
India.eCommerce@ge.com
Grievance Officer: Nestor J. Rivera
Chief Privacy Counsel/Officer, GE HealthCare